Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 6,129

Document Document Title
WO/2009/001356A3
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...  
WO/2009/024493A2
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...  
WO/2009/025829A1
Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 5O0C and below t...  
WO/2008/139121A3
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...  
WO/2009/019199A1
The present invention relates to a new crystalline form of R-4- trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical composition...  
WO/2009/015485A1
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...  
WO/2009/013915A1
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...  
WO/2009/009278A1
Treating pain in mammals with a compound having the formula (I) is disclosed herein.  
WO/2008/135181A3
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...  
WO/2009/001356A2
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...  
WO/2008/156816A2
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...  
WO/2008/113992A3
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...  
WO2008109991A8
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...  
WO/2008/143070A1
Disclosed is a non-covalently-bound polymer which is formed by the self-assembly of an urea compound including a long-chain-alkyl urea. Specifically disclosed is a novel non-covalently-bound polymer which has a simple chemical structure ...  
WO/2008/139121A2
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...  
WO/2008/135181A2
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...  
WO/2008/122667A2
The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.  
WO/2008/113992A2
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...  
WO/2008/008433A3
This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or dis...  
WO2007068394A8
The invention relates to novel specifically trifluoromethyl and halogen substituted 1 ,3- diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects l...  
WO/2008/116145A2
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co...  
WO/2008/109991A1
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...  
WO/2008/070496A3
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...  
WO/2008/107661A1
There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which...  
WO/2008/107475A1
The present invention relates to dialdimines of formula (I) and emulsions and uses thereof. In particular, paste-like hardener and/or accelerator components for polymers having isocyanate groups can be produced therefrom, which component...  
WO/2008/104756A1
A compound of formula (I) wherein R1 is C1-6 alkyl optionally substituted by OH, C1-4 alkyl, SH, C1-4 alkylthio, phenyl or indol-3-yl, wherein C1-4 alkyl and C1-4 alkylthio are optionally substituted by phenyl and indol-3-yl is optionall...  
WO/2008/079683A3
The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders ...  
WO/2008/099221A1
Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.  
WO/2008/079972A3
The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol- 5-yl}carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-car boxamide and alternativs forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and meta...  
WO/2008/040947A3
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...  
WO/2008/086047A1
Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases,...  
WO/2008/082735A1
Storage-stable organosilane quaternary compounds are provided in the form of adducts with urea (clathrates). The urea-organosilane quaternary clathrates enable the shipment, storage and preparation of compositions without hazardous solve...  
WO/2008/083054A2
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...  
WO/2008/079683A2
The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders ...  
WO/2008/079972A2
The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol- 5-yl}carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-car boxamide and alternativs forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and meta...  
WO/2008/078762A1
Disclosed are: a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of the pharmacological activity of the derivative. A compou...  
WO/2008/074132A1
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...  
WO/2008/075150A1
The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R1 is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 2,2-dihydroxyethyl, 3,3-dihydroxypropyl,...  
WO/2008/070496A2
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...  
WO/2008/062859A1
A process for the production of phenylalanine derivatives having quinazolinedione rings as represented by the general formula (1) or pharmaceutically acceptable salts thereof:(1) which comprises the following steps (a), (b) and (c): the ...  
WO/2008/059299A1
The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands fo...  
WO/2008/006625A3
Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in whi...  
WO/2008/040947A2
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...  
WO/2008/031755A1
The invention relates to processes for preparing isocyanates by splitting urethane, said process comprising the following process steps: (i) provision of synthesis gas from natural gas, coal, heavy oil or biomass gasification and product...  
WO/2007/133531A3
A composition comprising a self-emulsifiable or self-dispersible aqueous solution or dispersion of at least one urea linkage-containing alkoxypolyoxyalkylene fluorocarbamate prepared by contacting (a) at least one polyisocyanate which co...  
WO/2008/022938A1
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...  
WO/2007/119042A3
The present invention relates to a process for the treatment of a product stream, more specifically of a product stream from an autothermal cracking process, said product stream comprising one or more olefins, hydrogen, carbon monoxide, ...  
WO/2008/015081A1
The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I). The invention also relates to pharmaceutical compositions, which comprise at least one new compound according...  
WO/2007/137103A3
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.  
WO/2008/006625A2
Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in whi...  

Matches 351 - 400 out of 6,129